Cassava Sciences (NASDAQ:SAVA - Get Free Report) issued its earnings results on Thursday, August 14th. The company reported ($0.18) EPS for the quarter, Zacks reports.
Cassava Sciences Trading Up 0.5%
Shares of NASDAQ:SAVA traded up $0.01 during trading hours on Thursday, hitting $2.15. The company's stock had a trading volume of 313,402 shares, compared to its average volume of 796,943. The firm's fifty day moving average price is $2.15 and its 200 day moving average price is $2.08. Cassava Sciences has a 52 week low of $1.15 and a 52 week high of $33.98.
Institutional Trading of Cassava Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jump Financial LLC bought a new stake in Cassava Sciences during the 2nd quarter valued at $50,000. Marshall Wace LLP bought a new stake in Cassava Sciences during the second quarter valued at about $130,000. AQR Capital Management LLC bought a new position in Cassava Sciences in the first quarter worth about $120,000. Strs Ohio purchased a new stake in shares of Cassava Sciences during the first quarter valued at about $178,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Cassava Sciences by 77.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 496,313 shares of the company's stock worth $744,000 after buying an additional 217,404 shares during the last quarter. Institutional investors own 38.05% of the company's stock.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Read More
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
